Bladder Cancer Care is Changing: What Every Clinician Needs to Know in 2025

Bladder cancer is the 10th leading cause of cancer-related deaths in the United States. In 2025, an estimated 84,870 new cases will be diagnosed, with 17,420 deaths expected. Globally, approximately 614,298 people were diagnosed with bladder cancer in 2022. Empowering healthcare professionals, patients, and communities with the knowledge to navigate bladder cancer care is essential. Early detection and timely diagnosis are vital, both of which are core pillars of Binaytara’s global oncology efforts.

First-line treatment strategies for metastatic urothelial carcinoma (mUC) and muscle-invasive bladder cancer (MIBC) are evolving rapidly. Staying up to date with emerging therapies is critical for improving outcomes. In response to this need, Binaytara has launched a new free CME course on OncoBlast, which explores recent changes in the NCCN Guidelines and the latest advances in first-line treatment for mUC and MIBC.

The Shift in First-Line Management of mUC and MIBC

The 2025 NCCN Guidelines for bladder cancer highlight a significant shift toward precision medicine, integrating immunotherapy and targeted agents earlier in the treatment course, emphasizing molecular testing, and refining both surgical and systemic approaches for muscle-invasive and metastatic urothelial carcinoma. These changes reflect the clinical impact of recent approvals, particularly involving checkpoint inhibitors and combination therapies. For example, the concurrent chemoradiotherapy pathway has been removed as a primary treatment option in certain advanced cases, further emphasizing the move toward immunotherapy-based strategies.

Free CME Opportunity: What the OncoBlast Course Covers

This new course on OncoBlast, entitled ‘Navigating the Shift: New NCCN Guidelines and Emerging Therapies in First-line mUC and MIBC’, delivers key updates on first-line treatment of mUC and MIBC. Through gamified, interactive case scenarios, the course offers education on guideline-based care, optimal treatment sequencing, and strategies for managing adverse events. This free CME course supports the real-world application of evolving evidence in urothelial cancer management. Designed for busy healthcare professionals, completion of this CME activity will enable participants to do the following:

• Summarize current guideline-recommended first-line therapies and sequencing strategies for advanced urothelial carcinoma.
• Apply a multidisciplinary, patient-centered approach to treatment planning in mUC and MIBC.
• Identify and manage treatment-related adverse events, including those associated with antibody-drug conjugate.

Why It is Worth Your Time (and Your Patients’)

This free CME course is short, practical, and built with busy healthcare professionals in mind. Participants who complete the course can earn free CME credits and Maintenance of Certification (MOC) points, all at no cost.

The course is supported by an Independent Medical Education Grant from Pfizer and was developed by Dr. Jordan Ciuro, a board-certified medical oncologist at the Emory Winship Cancer Institute. Dr. Ciuro specializes in genitourinary cancers, including adrenal, bladder, kidney, penile, prostate, and testicular cancers. She is triple board-certified in Internal Medicine, Medical Oncology, and Hematology by the American Board of Internal Medicine and has been practicing since 2022.

In addition to her clinical expertise, Dr. Ciuro has contributed to peer-reviewed journals such as BMJ Case Reports and the Mathews Journal of Case Reports. Recognized for her patient-centered care, she consistently receives high satisfaction scores, reflecting her commitment to compassionate and inclusive oncology care.

New treatments and updated guidelines based on emerging data can significantly influence the prognosis of bladder cancer patients. Therefore, completing our CME course will ensure that clinicians make decisions based on the most current evidence, which will, in turn, enhance patient outcomes.

How to Access the Course

Want a quick, fun, and engaging way to learn about the new NCCN Guidelines and emerging therapies in first-line mUC and MIBC and earn CME credits and MOC points while at it?

Download OncoBlast from the App Store or Google Play, and start the course today! You can choose between Geek Mode, a classic multiple-choice format, or Fun Mode, which offers an interactive, game-style experience.

This free CME course is accredited by the Washington State Medical Association, the California Board of Registered Nursing, and the American Board of Internal Medicine (ABIM). Upon completion and evaluation, participants can earn:

• 1 AMA PRA Category 1 Credit™
• 1 Nursing Contact Hour
• 1 ABIM MOC Point

In under 30 minutes, you will tackle 12 questions that walk you through the latest treatment guidelines and the growing role of antibody-drug conjugates in bladder cancer care.

Start the course now and stay ahead in your practice.

Bladder Cancer Awareness Is More Than a Hashtag

Bladder Cancer Awareness Month is a reminder each May of the importance of recognizing symptoms early, but timely diagnosis is only the beginning. Equally critical is making the right clinical management decisions once a diagnosis is confirmed.

Our latest free CME course takes a case-based approach to test and strengthen participants’ knowledge of optimal treatment strategies based on a patient’s medical history and clinical profile.

Share this course with colleagues, medical oncologists, fellows, nurses, physician assistants, and pharmacists, who play vital roles in the care of bladder cancer patients.

Available on the OncoBlast app, this course is one of several free CME offerings designed to help healthcare professionals expand their expertise anytime, anywhere. Our mission is to transform oncology education by making it more engaging, accessible, and rewarding. As one oncologist from Fred Hutchinson Cancer Center said, “Gaming and learning! You can do both at the same time.”